
Revolution Medicines
OrganizationHeard in 5 episodes across 5 shows since Aug 2026
Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering targeted medicines for patients with RAS-addicted cancers. Its pipeline includes RAS pathway inhibitors, including daraxonrasib (RMC-6236).
Episodes
5
across 5 shows
First heard
Aug 2026
Episodes per month
Public PodLume episodes featuring it, over the last year.
3
2
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 3 |
| Sep 2026 | 2 |
| Oct 2026 | 0 |
Episodes
5 episodes featuring Revolution Medicines, newest first
- Sep 13, 2026
Biotech’s rally tests the promise of cancer breakthroughsWSJ's Take On the WeekSep 13, 2026 - Sep 2, 2026
Moderna turns tumor mutations into personalized cancer vaccinesThe a16z ShowSep 2, 2026 - Aug 28, 2026
Markets await Fed clarity as Shein cuts IPO ambitionsMorning Brew DailyAug 28, 2026 - Aug 26, 2026
Markets weigh Meta safeguards, Nvidia expectations and cancer-drug promiseStock MoversAug 26, 2026 - Aug 26, 2026
Meta settlement puts teen-platform safeguards under scrutinyWSJ What’s NewsAug 26, 2026